Among baseline nonusers of statins and after censoring at the time of statin initiation throughout follow-up, APOE4+ carriers had significantly higher incidence of total CVD (1.18 [1.02–1.38], p = .03), though not CHD composite (1.09 [0.87–1.36], p = .47) or stroke composite (1.14 [0.91–1.44], p = .27), compared with APOE3 carriers in adjusted analysis (Table 3). Here, APOE is linked to Stroke.